Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey

We retrospectively evaluated the use of gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) acute myeloid leukemia (AML) patients. Twenty-one CD33 positive R/R AML patients who received GO as a single agent in 4 hematology centers were included in this study. The median age was 59, and the media...

Descripción completa

Detalles Bibliográficos
Autores principales: Küçükdiler, Ayşe Hilal Eroğlu, Yavaşoğlu, İrfan, Selim, Cem, Mutlu, Cansu Atmaca, Karakuş, Abdullah, Koyuncu, Mahmut Bakır, Bilgir, Oktay, Ayyıldız, Orhan, Tiftik, Eyüp Naci, Bolaman, Ali Zahit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608612/
https://www.ncbi.nlm.nih.gov/pubmed/34849337
http://dx.doi.org/10.1016/j.lrr.2021.100280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608612/
https://www.ncbi.nlm.nih.gov/pubmed/34849337
http://dx.doi.org/10.1016/j.lrr.2021.100280

Ejemplares similares